Solid Bio Gets Orphan Designation for Duchenne Gene Therapy

 Patient dosing expected to begin mid-to-late Q1 2024 –

 Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate.

https://www.globenewswire.com/news-release/2024/01/16/2809854/0/en/Solid-Biosciences-Granted-FDA-Orphan-Drug-Designation-for-Duchenne-Muscular-Dystrophy-Gene-Therapy-Candidate-SGT-003.html